The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Research Report 2024
Synopsis
The global Gastroesophageal Reflux Disease (GERD) Therapeutics market was valued at US$ 4801.8 million in 2023 and is anticipated to reach US$ 4286.6 million by 2030, witnessing a CAGR of -1.6% during the forecast period 2024-2030.
North American market for Gastroesophageal Reflux Disease (GERD) Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Gastroesophageal Reflux Disease (GERD) Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Gastroesophageal Reflux Disease (GERD) Therapeutics in Heartburn is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Gastroesophageal Reflux Disease (GERD) Therapeutics include AstraZeneca, Eisai, GSK, Takeda and Johnson & Johnson, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Gastroesophageal Reflux Disease (GERD) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gastroesophageal Reflux Disease (GERD) Therapeutics.
Report Scope
The Gastroesophageal Reflux Disease (GERD) Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Gastroesophageal Reflux Disease (GERD) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gastroesophageal Reflux Disease (GERD) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
Eisai
GSK
Takeda
Johnson & Johnson
Segment by Type
Antacids
Pro-kinetic agents
H2 Receptor Blockers
Proton Pump Inhibitors (PPIs)
Segment by Application
Heartburn
Acid reflux disorders
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gastroesophageal Reflux Disease (GERD) Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Gastroesophageal Reflux Disease (GERD) Therapeutics market was valued at US$ 4801.8 million in 2023 and is anticipated to reach US$ 4286.6 million by 2030, witnessing a CAGR of -1.6% during the forecast period 2024-2030.
North American market for Gastroesophageal Reflux Disease (GERD) Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Gastroesophageal Reflux Disease (GERD) Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Gastroesophageal Reflux Disease (GERD) Therapeutics in Heartburn is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Gastroesophageal Reflux Disease (GERD) Therapeutics include AstraZeneca, Eisai, GSK, Takeda and Johnson & Johnson, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Gastroesophageal Reflux Disease (GERD) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gastroesophageal Reflux Disease (GERD) Therapeutics.
Report Scope
The Gastroesophageal Reflux Disease (GERD) Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Gastroesophageal Reflux Disease (GERD) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gastroesophageal Reflux Disease (GERD) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
Eisai
GSK
Takeda
Johnson & Johnson
Segment by Type
Antacids
Pro-kinetic agents
H2 Receptor Blockers
Proton Pump Inhibitors (PPIs)
Segment by Application
Heartburn
Acid reflux disorders
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gastroesophageal Reflux Disease (GERD) Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Antacids
1.2.3 Pro-kinetic agents
1.2.4 H2 Receptor Blockers
1.2.5 Proton Pump Inhibitors (PPIs)
1.3 Market by Application
1.3.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Heartburn
1.3.3 Acid reflux disorders
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Perspective (2019-2030)
2.2 Gastroesophageal Reflux Disease (GERD) Therapeutics Growth Trends by Region
2.2.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Gastroesophageal Reflux Disease (GERD) Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Gastroesophageal Reflux Disease (GERD) Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Gastroesophageal Reflux Disease (GERD) Therapeutics Market Dynamics
2.3.1 Gastroesophageal Reflux Disease (GERD) Therapeutics Industry Trends
2.3.2 Gastroesophageal Reflux Disease (GERD) Therapeutics Market Drivers
2.3.3 Gastroesophageal Reflux Disease (GERD) Therapeutics Market Challenges
2.3.4 Gastroesophageal Reflux Disease (GERD) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gastroesophageal Reflux Disease (GERD) Therapeutics Players by Revenue
3.1.1 Global Top Gastroesophageal Reflux Disease (GERD) Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue
3.4 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Concentration Ratio
3.4.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue in 2023
3.5 Gastroesophageal Reflux Disease (GERD) Therapeutics Key Players Head office and Area Served
3.6 Key Players Gastroesophageal Reflux Disease (GERD) Therapeutics Product Solution and Service
3.7 Date of Enter into Gastroesophageal Reflux Disease (GERD) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Gastroesophageal Reflux Disease (GERD) Therapeutics Breakdown Data by Type
4.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Forecasted Market Size by Type (2025-2030)
5 Gastroesophageal Reflux Disease (GERD) Therapeutics Breakdown Data by Application
5.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size (2019-2030)
6.2 North America Gastroesophageal Reflux Disease (GERD) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Country (2019-2024)
6.4 North America Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size (2019-2030)
7.2 Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Country (2019-2024)
7.4 Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size (2019-2030)
9.2 Latin America Gastroesophageal Reflux Disease (GERD) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Detail
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Gastroesophageal Reflux Disease (GERD) Therapeutics Introduction
11.1.4 AstraZeneca Revenue in Gastroesophageal Reflux Disease (GERD) Therapeutics Business (2019-2024)
11.1.5 AstraZeneca Recent Development
11.2 Eisai
11.2.1 Eisai Company Detail
11.2.2 Eisai Business Overview
11.2.3 Eisai Gastroesophageal Reflux Disease (GERD) Therapeutics Introduction
11.2.4 Eisai Revenue in Gastroesophageal Reflux Disease (GERD) Therapeutics Business (2019-2024)
11.2.5 Eisai Recent Development
11.3 GSK
11.3.1 GSK Company Detail
11.3.2 GSK Business Overview
11.3.3 GSK Gastroesophageal Reflux Disease (GERD) Therapeutics Introduction
11.3.4 GSK Revenue in Gastroesophageal Reflux Disease (GERD) Therapeutics Business (2019-2024)
11.3.5 GSK Recent Development
11.4 Takeda
11.4.1 Takeda Company Detail
11.4.2 Takeda Business Overview
11.4.3 Takeda Gastroesophageal Reflux Disease (GERD) Therapeutics Introduction
11.4.4 Takeda Revenue in Gastroesophageal Reflux Disease (GERD) Therapeutics Business (2019-2024)
11.4.5 Takeda Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Detail
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Gastroesophageal Reflux Disease (GERD) Therapeutics Introduction
11.5.4 Johnson & Johnson Revenue in Gastroesophageal Reflux Disease (GERD) Therapeutics Business (2019-2024)
11.5.5 Johnson & Johnson Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
